PREFILLED SYRINGES MARKET ANALYSIS

Prefilled Syringes Market, by Material (Glass, Plastic/Polymer), by Drug Type (Biologics, Vaccines, Insulin, Anticoagulants, Flush Saline Syringes and Others), by Design (Single-chamber, Dual-chamber, and Multi-chambered), by Product Type (Staked in-needle pre-filled syringes and Needle-free pre-filled syringes), by Usability (Disposable and Reusable), by Manufacturing Method (Captive and Merchant), by End User (Hospitals, Clinics, Ambulatory Surgical Centers and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023
Code : CMI162
Pages :401
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Prefilled Syringes Market: Key Developments

For instance, on January 4, 2023, Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, announced that it had launched Naloxone Hydrochloride Injection, USP, 2mg/2mL, in prefilled syringe (PFS) form in the U.S. It is used for the emergency treatment of a known or suspected opioid overdose.

For instance, Clemson University, a public research institution, and Nephron Pharmaceuticals Corporation, a privately held company, developed a benchtop robot in March 2021 that can fill, cap, and seal sterile prefilled syringes, which can reduce costs by preventing drug overfill and minimizing contamination. Filling syringes in the absence of a robot is a highly regulated process that needs to be undertaken by specialized technicians under ISO-certified clean rooms. The robot is expected to help in addressing the shortage of prefilled syringes in hospitals and healthcare facilities.

In November 2022, Tjoapack, a contract packaging organization, invested in a new packaging line for pre-filled syringes (PFS) and vials at its production facilities in both Europe and the U.S. The PFS line can pack pre-filled syringes of 1 to 5ml, with or without safety devices, and other customer-specific components can also be added.

In April 2021, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) had approved the company’s supplemental Biologics License Application for Xolair (omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only U.S. FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU), and nasal polyps.